Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with multiple myeloma.
Sarah Holstein, MD, PhD
The benefit of adding monoclonal antibodies to upfront induction therapy in patients with multiple myeloma is currently being looked at in ongoing trials.
The current standard therapy of lenalidomide (Revlimid) plus bortezomib (Velcade) and dexamethasone (RVd) is quite beneficial for newly diagnosed patients, said Sarah Holstein, MD, PhD, with triplets quickly replacing doublets in this setting. However, quadruplet therapy is currently showing promise in clinical trials.
In May 2018, the FDA approved daratumumab (Darzalex) in combination with bortezomib, melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This approval was based on findings of the ALCYONE study, which showed that the addition of daratumumab to VMP demonstrated a 50% reduction in the risk of progression or death compared with VMP alone (HR, 0.50; 95% CI, 0.38-0.65;P<.001).1
An interim safety analysis of daratumumab plus RVd was presented at the 2017 ASH Annual Meeting.2These safety results concluded that there were no added safety signals with the addition of daratumumab to the triplet. Investigators noted that the overall safety profile was consistent, and enrollment has begun on the main phase of the randomized study.
Additionally, daratumumab is currently being investigated in combination with carfilzomib (Kyprolis), lenalidomide, and dexamethasone (KRd). The addition of daratumumab to this triplet has shown to be well tolerated in patients with newly diagnosed myeloma, according to updated results of a phase Ib study presented at the 2017 ASH Annual Meeting.3
In an interview withTargeted Oncologyduring the 2018 Pan Pacific Lymphoma Conference, Holstein, an associate professor at the University of Nebraska Medical Center, discussed these new approaches to induction therapy for patients with myeloma.
TARGETED ONCOLOGY:Can you provide an overview of your presentation?
Holstein: I provided a historical overview of where we have come with respect to induction regimens, dating back to some of the old regimens such as vincristine, doxorubicin, and dexamethasone (VAD) and melphalan. I spoke about how we have moved from doublet to triplet therapies, with the current standard of care being combinations of immunomodulatory drugs and proteasome inhibitors.
I then spoke about the newer studies, which are investigating the effects of adding a monoclonal antibody therapy to the triplet. We are now moving into the quadruplet therapy era. I also touched on the role of transplant.
TARGETED ONCOLOGY:What need is aiming to be filled with the introduction of new induction therapies?
Right now, the current standard of care is RVd, which is lenalidomide, bortezomib, and dexamethasone. There are ongoing studies asking the question of whether we can improve upon that by adding the second-generation proteasome inhibitor carfilzomib instead of bortezomib. However, we know that especially for patients with high-risk disease, even though they initially do well, they have a much higher rate of relapse and live a shorter time progression free. The question is going to be, “Can we do something that will significantly change the outcomes for high-risk patients?”
TARGETED ONCOLOGY:What are some triplets or quadruplets that are looking most promising?
There is a lot of excitement about KRd, which is a triplet of carfilzomib, lenalidomide, and dexamethasone. There is also some interest with lenalidomide, ixazomib (Ninlaro), and dexamethasone in the older patient population as it is an all-oral regimen, which might be well tolerated. We are eagerly awaiting the results of a phase III study that has finished accruing, which compared lenalidomide plus dexamethasone to the triplet of lenalidomide, ixazomib, and dexamethasone to see whether that improved survival outcomes.
With respect to the quadruplets, the most interest so far is with adding antibodies such as daratumumab to the backbone of a proteasome inhibitor plus an immunomodulatory agent. This includes daratumumab plus RVd and daratumumab plus KRd. Initial studies are showing very high response rates, but we are going to need the larger studies to see if we are making significant changes in overall survival.
TARGETED ONCOLOGY:In what instance would you use a triplet of quadruplet over a doublet?
At this point, I am not using quadruplets outside the context of a clinical trials, because I don't think we are quite there yet. For the majority of my patients, I really try to use a triplet. It is really the patients who are quite elderly or frail who I will sometimes start on a doublet and see how well they can tolerate it. A lot of times, in that case, if I can get them past the first couple of cycles successfully, I will then try to add in that third drug.
TARGETED ONCOLOGY:What would be your takeaway message about induction therapy for patients with myeloma?
The current standard of care for all patients at this point in time should be RVd, that there is still a role for upfront transplant for the majority of transplant-eligible patients, and that there is going to be some exciting changes in what the standard of care will be over the next couple of years. The future likely will be quadruplet therapy.
TARGETED ONCOLOGY:Is there any else you would like to highlight?
I didn't have time to work it into the talk, but it is still really important to use maintenance therapy posttransplant for patients. There, the current standard of care is lenalidomide, but we are waiting on some exciting data about the use of ixazomib as maintenance therapy. There are also ongoing studies looking at regimens such as lenalidomide plus daratumumab. Maintenance therapy is also going to be changing over the next couple of years.